Ph.D. Noubar B. Afeyan - 12 May 2022 Form 4 Insider Report for Rubius Therapeutics, Inc.

Reporting relationship: Director, 10%+ Owner
Issuer ticker: N/A
Reported as of: 12 May 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 May 2022, 16:24:58 UTC
Prior SEC filing: 13 May 2022
Next SEC filing: 20 May 2022
Source filing: View source filing
Reporting owner signature: /s/ Joanne M. Protano, Attorney-in-Fact

Key filing fact

Ph.D. Noubar B. Afeyan filed Form 4 for Rubius Therapeutics, Inc. on 13 May 2022.

Key facts

This page summarizes Ph.D. Noubar B. Afeyan's Form 4 filing for Rubius Therapeutics, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 May 2022, 16:24.

Change

Previous filing in this sequence was filed on 13 May 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RUBY transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +25,000
Change %
Price: $0.000000
Shares after: 25,000
Date: 12 May 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $1.24
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service.